Drug Type Small interfering RNA |
Synonyms N-Acetylgalactosamine-siRNA /shRNA-expressing adeno-associated virus vector (Alnylam Pharmaceuticals/Technical University of Helmholtz/ University of Heidelberg), TherVacB |
Target- |
Mechanism Gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 1 | DE | 14 Feb 2023 | |
Hepatitis B | Preclinical | US | - | |
Hepatitis B | Preclinical | DE | - | |
Hepatitis B | Preclinical | DE | - | |
Hepatitis B | Preclinical | DE | - |